PDF icon Download PDF
Open Access
CC BY 4.0 · Eur J Dent 2023; 17(01): 024-038
DOI: 10.1055/s-0042-1751003
Review Article

Onset of Mucormycosis in Patients with COVID-19: A Systematic Review on Patients' Characteristics

Shohreh Ghasemi 
1   Department of Oral and Maxillofacial Surgery, The Dental College of Georgia at Augusta University, Augusta, GA, USA
2   Department of Craniofacial Reconstruction and Trauma Queen Marry, University of London, London, UK
,
Mahmood Dashti 
3   Department of Orthodontics, Georgia School of Orthodontics, Atlanta, Georgia, USA
,
Amir Fahimipour 
4   Department of Oral Surgery, Medicine and Diagnostics, School of Dentistry, Faculty of Medicine and Health, Westmead Centre for Oral Health, The University of Sydney, Sydney, Australia
,
Ghazaleh Daryakenari 
5   Department of Oral and Maxillofacial Surgery, Student Research Committee, Golestan University of Medical Sciences, Gorgan, Iran
,
Fatemeh Mirzaei 
6   Student Research Committee, Golestan University of Medical Sciences, Gorgan, Iran
,
Fatemeh Akbari 
7   Department of Dentistry, Mazandaran University of Medical Science, Mazandaran, Iran
,
Zohaib Khurshid
8   Department of Prosthodontics and Dental Implantology, College of Dentistry, King Faisal University, Al-Ahsa, Kingdom of Saudi Arabia
› Author Affiliations
Funding None.
› Further Information
Also available ateRef
  Permissions and Reprints
Preview

Abstract

Mucormycosis has a significant impact on patients' standard of living and, therefore, a high clinical suspicion, prediagnosis, and rapid treatment are critical in easing patients' suffering and fast recovery. Our focus is to conduct an organized review based on various variables on the patients' characteristics having mucormycosis in severe novel coronavirus disease 2019 (COVID-19). We examined Embase, PubMed-Medline, LitCovid, Web of Science, Scopus, and the reference lists of included case reports up to September 20, 2021, using the Medical Subject Heading (MeSH) phrases and other keywords related to this topic. Subsequently, we investigated associated comorbidities, patient characteristics, position of mucormycosis, steroids use, body involvements, and outcomes. Overall, 77 studies were conducted and among these, 72 studies mentioned that the patients' age to be 48.13±14.33 (mean±standard deviation [SD]) years. Diabetes mellitus (DM) was reported in 77.9% (n=60) of cases. Studies showed that central nervous system (CNS) and bone involvement were reported in 62.3 (n=48) and 53.2% (n=41), respectively. More fatalities were observed in patients with mucormycosis with the active form of COVID-19. Also, men infected with mucormycosis significantly affected by COVID-19. In the end, mortality was higher in males with mucormycosis. As a result, a solid investigation into the root cause of mucormycosis, especially in COVID-19, should be included in the study plan. If the patient is COVID-19-positive and immunosuppressed, this opportunistic pathogen diagnostic test should not be overlooked.

Keywords

novel coronavirus disease 2019 - COVID-19-associated candidiasis - mucormycosis - corticosteroid treatment - fungal co infections

Consent for Publication

All authors, give their consent for the publication of identifiable details which can include photograph(s) and/or videos and/or case history and/or details within the text (“Material”) to be published in the above Journal and Article.


Availability of Data and Materials

All data generated or analyzed during this study are included in this published article (and its supplementary information files).


Authors' Contributions

S.G. and M.D. conceptualized; F.A. and F.M. searched the literature and created the first draft; M.D. created the table and analyzed the data; A.F and G.D.K. prepared the first draft; And S. G., M.D., and Z.K. reviewed the first draft and edited the final draft. All authors mutually agree to submit for publication.




Publication History

Article published online:
01 September 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India